

NEWS RELEASE
FOR IMMEDIATE RELEASE

Company Contact:
Stan Fronczkowski
Chief Financial Officer
(302) 456-6789
www.sdix.com

Investor Contact:
Hayden Communications
Brett Maas (brett@haydenir.com)
(646) 536-7331

Strategic Diagnostics to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference April 3

Scheduled to present at 9:30 a.m.

NEWARK, Del., March 25, 2008 - Strategic Diagnostics Inc. (Nasdaq: SDIX) announced today that its Chief Financial Officer, Stan Fronczkowski, and Chief Commercial Officer, Fran DiNuzzo, will present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference at the Palms Hotel and Casino in Las Vegas. Strategic Diagnostics is scheduled to present at 9:30 a.m. (Pacific) on April 3, 2008 in the Jazz A room. The Company will be available for one-on-one meetings throughout the day. Interested attendees may schedule the one-on-one meetings directly through B. Riley & Co.

The presentation will be webcast at <http://www.wsw.com/webcast/brileyco9/sdix/> for approximately 30 days following the conclusion of the presentation.

The presentation is intended to provide attending analysts, institutional brokers and portfolio managers with an overview of the Company's expertise in the production of antibodies. SDI's antibodies are used in diagnostic tests and also provided to prominent customers in the proteomics, pharmaceutical, diagnostics and biomedical research industries to enable rapid discovery and commercialization of products. Strategic Diagnostics is also a leader in the food pathogen industry, providing comprehensive, accurate, and easy-to-use tests including the recently introduced RapidChek® SELECT™ *Salmonella* product. The Company's patent-pending technology also addresses renewable energy opportunities and can be used to increase efficiency in the production of ethanol. Mr. Fronczkowski will discuss the recurring revenue component of the Company's business model, revenue potential from new product and services, and the Company's strategy for sustainable growth.

About B. Riley & Co.

Headquartered in Los Angeles, with offices in San Francisco, New York, and Newport Beach, B. Riley is a NASD member firm providing research and trading ideas to institutional clients and high net worth individuals, and investment banking services to a wide range of middle-market private and public companies. Founded in 1997, the firm began by successfully targeting small capitalization California-based companies and has won a reputation for providing proprietary, unbiased and often contrarian Equity and High Yield research coverage of companies that are under-followed or misunderstood by Wall Street. The B. Riley & Co. 9th Annual Las Vegas Conference will feature presentations by 150 companies in a variety of industries.

About Strategic Diagnostics Inc.

Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By

applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable “return on investment” by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company’s established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in proteomics research and discovery.

This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.

#